Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium, Showing Promising Safety and Efficacy Results for Investigational OMNYPULSE Platform.

Johnson & Johnson presented 12-month pilot-phase data from the OMNY-AF study, evaluating the OMNYPULSE Platform for symptomatic paroxysmal atrial fibrillation treatment. Initial results showed 100% acute procedural success, zero fluoroscopy in 56.7% of cases, and 90% primary effectiveness at 12 months. The OMNYPULSE Catheter and TRUPULSE Generator are designed for precise mapping, controlled energy delivery, and live feedback through the PF index on the CARTO 3 System. The OMNYPULSE Platform is not currently approved in any region.